Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab vs Denosumab for Bone Loss in Subacute SCI
NCT05101018Phase 4Active, not recruiting
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Start
- Nov 2021
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of romosozumab in osteoporosis (2 arms), sponsored by James J. Peters Veterans Affairs Medical Center. Primary endpoint: Bone Mineral Density of the distal femur metaphysis at 24 months. Started Nov 2021; status: active, not recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05101018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101018.